PROCEPT BioRobotics Corporation Gross Profit
PROCEPT BioRobotics Corporation (PRCT) reported Gross Profit of $62.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:GrossProfit · last filed 2026-08-05
- PROCEPT BioRobotics Corporation gross profit for the quarter ending 2026-06-30 was $62.38M, a 20.55% increase year-over-year.
- PROCEPT BioRobotics Corporation gross profit for the quarter ending 2026-03-31 was $53.95M, a 22.16% increase year-over-year.
- PROCEPT BioRobotics Corporation gross profit for the quarter ending 2025-12-31 was $46.31M, a 6.05% increase year-over-year.
- PROCEPT BioRobotics Corporation gross profit for the quarter ending 2025-09-30 was $54.01M, a 46.31% increase year-over-year.
- PROCEPT BioRobotics Corporation gross profit for fiscal 2025 was $196.23M, a 43.13% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation gross profit for fiscal 2024 was $137.10M, a 92.96% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation gross profit for fiscal 2023 was $71.05M, a 91.58% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation gross profit for fiscal 2022 was $37.09M, a 133.75% increase from fiscal 2021.
| Period end | Gross Profit 3 month | Gross Profit 6 month | Gross Profit 9 month | Gross Profit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.38M 10-Q · filed 2026-08-05 | $116.33M 10-Q · filed 2026-08-05 | $162.64M derived: sum of 3 quarters · filed 2026-08-05 | $216.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $53.95M 10-Q · filed 2026-04-30 | $100.26M derived: sum of 2 quarters · filed 2026-04-30 | $154.27M derived: sum of 3 quarters · filed 2026-04-30 | $206.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $46.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $100.32M derived: sum of 2 quarters · filed 2026-02-26 | $152.06M derived: sum of 3 quarters · filed 2026-08-05 | $196.23M 10-K · filed 2026-02-26 |
| 2025-09-30 | $54.01M 10-Q · filed 2025-11-05 | $105.75M derived: sum of 2 quarters · filed 2026-08-05 | $149.91M 10-Q · filed 2025-11-05 | $193.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $51.75M 10-Q · filed 2026-08-05 | $95.91M 10-Q · filed 2026-08-05 | $139.58M derived: sum of 3 quarters · filed 2026-08-05 | $176.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $44.16M 10-Q · filed 2026-04-30 | $87.83M derived: sum of 2 quarters · filed 2026-04-30 | $124.74M derived: sum of 3 quarters · filed 2026-04-30 | $156.23M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $43.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $80.58M derived: sum of 2 quarters · filed 2026-02-26 | $112.06M derived: sum of 3 quarters · filed 2026-02-26 | $137.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $36.91M 10-Q · filed 2025-11-05 | $68.39M derived: sum of 2 quarters · filed 2025-11-05 | $93.43M 10-Q · filed 2025-11-05 | $114.68M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $31.48M 10-Q · filed 2025-08-07 | $56.52M 10-Q · filed 2025-08-07 | $77.77M derived: sum of 3 quarters · filed 2026-02-26 | $96.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $25.03M 10-Q · filed 2025-05-02 | $46.29M derived: sum of 2 quarters · filed 2026-02-26 | $65.16M derived: sum of 3 quarters · filed 2026-02-26 | $83.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $40.13M derived: sum of 2 quarters · filed 2026-02-26 | $58.56M derived: sum of 3 quarters · filed 2026-02-26 | $71.05M 10-K · filed 2026-02-26 |
| 2023-09-30 | $18.87M 10-Q · filed 2024-10-28 | $37.30M derived: sum of 2 quarters · filed 2024-10-28 | $49.79M 10-Q · filed 2024-10-28 | $60.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $18.43M 10-Q · filed 2024-08-02 | $30.92M 10-Q · filed 2024-08-02 | $41.60M derived: sum of 3 quarters · filed 2025-02-27 | $51.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $12.49M 10-Q · filed 2024-05-02 | $23.17M derived: sum of 2 quarters · filed 2025-02-27 | $33.40M derived: sum of 3 quarters · filed 2025-02-27 | $41.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $10.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $20.91M derived: sum of 2 quarters · filed 2025-02-27 | $29.39M derived: sum of 3 quarters · filed 2025-02-27 | $37.09M 10-K · filed 2025-02-27 |
| 2022-09-30 | $10.23M 10-Q · filed 2023-11-02 | $18.72M derived: sum of 2 quarters · filed 2023-11-02 | $26.41M 10-Q · filed 2023-11-02 | $30.93M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $8.49M 10-Q · filed 2023-07-28 | $16.18M 10-Q · filed 2023-07-28 | $20.69M derived: sum of 3 quarters · filed 2024-02-28 | $24.93M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $7.69M 10-Q · filed 2023-05-04 | $12.21M derived: sum of 2 quarters · filed 2024-02-28 | $16.45M derived: sum of 3 quarters · filed 2024-02-28 | $20.03M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $8.76M derived: sum of 2 quarters · filed 2024-02-28 | $12.34M derived: sum of 3 quarters · filed 2024-02-28 | $15.87M 10-K · filed 2024-02-28 |
| 2021-09-30 | $4.24M 10-Q · filed 2022-11-04 | $7.82M derived: sum of 2 quarters · filed 2022-11-04 | $11.35M 10-Q · filed 2022-11-04 | $11.82M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $3.58M 10-Q · filed 2022-08-05 | $7.11M 10-Q · filed 2022-08-05 | $7.58M derived: sum of 3 quarters · filed 2022-08-05 | $7.55M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $3.53M 10-Q · filed 2022-05-06 | $4.00M derived: sum of 2 quarters · filed 2022-05-06 | $3.97M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $470.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $439.00K derived: sum of 2 quarters · filed 2022-03-22 | -$1.25M 10-K · filed 2022-03-22 | |
| 2020-09-30 | -$31.00K 10-Q · filed 2021-11-05 | -$1.73M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |